TSTickerStarGet alerts

EVMN 10-Q filed 2026-11-12 | Key takeaways

EVMN filed its 10-Q; the most relevant disclosure change is added Subsequent events - Hinova license agreement: In November 2026, the company entered a license agreement with Hinova Pharmaceuticals Inc. for exclusive worldwide rights (excluding Greater China) to EVO570, an oral VAV1 molecular glue degrader, with $20.0M upfront cash payment, $10.0M in pre-funded warrants.

Share this story

Key takeaways

  • EVO756 discontinued for CSU and AD: Phase 2b trials for both indications failed to meet primary endpoints; development continues only for migraine with Phase 2b initiated in July 2026 and results expected in H2 2027.

  • Hinova license agreement: Exclusive worldwide rights (ex-China) for EVO570 VAV1 molecular glue degrader with $20.0M upfront cash, $10.0M in pre-funded warrants, up to $1.1B in potential milestones, and mid single-digit to low double-digit royalties.

  • November 2026 private placement: 4,966,889 shares at $6.04 per share for gross proceeds of $30.0M.

  • Subsequent event milestone: $5.0M development milestone payment received in October 2026 from Maruho Greater Asia for EVO756 Phase 2b CSU trial completion.

  • New pre-clinical program EVO646: Oral TLR 7/8 antagonist with Phase 1 trials planned for H1 2027.

  • Cash position: $262.3M in cash, cash equivalents, and investments as of September 30, 2026; runway extended into second half of 2029.

  • New risk factors added: AI-powered solutions risks, China dependency risks for EVO570, U.S.-China regulatory/policy risks, and Hinova dependency risks.

Key metrics

Net loss - Q3Q3 2026
$(30.9) millionQ3 2025: $(12.5) million
Net loss - Nine months9M 2026
$(84.8) million9M 2025: $(40.6) million
Revenue - Q3Q3 2026
$0Q3 2025: $10.0 million
Revenue - Nine months9M 2026
$09M 2025: $13.0 million
R&D expenses - Q3Q3 2026
$24.6 millionQ3 2025: $19.6 million
R&D expenses - Nine months9M 2026
$68.3 million9M 2025: $53.6 million
G&A expenses - Q3Q3 2026
$8.8 millionQ3 2025: $3.7 million
G&A expenses - Nine months9M 2026
$23.9 million9M 2025: $10.7 million

Disclosure changes

  • Subsequent events - Hinova license agreement

    In November 2026, the company entered a license agreement with Hinova Pharmaceuticals Inc. for exclusive worldwide rights (excluding Greater China) to EVO570, an oral VAV1 molecular glue degrader, with $20.0M upfront cash payment, $10.0M in pre-funded warrants (1,262,413 shares), up to $1.1B in potential development, regulatory, and commercial milestones, and tiered royalties from mid single-digits to low double-digits on net sales.

    Major strategic transaction adding a new pre-clinical program with significant milestone and royalty potential; upfront payment and warrant issuance will impact Q4 2026 financials
  • Subsequent events - November 2026 private placement

    In November 2026, the company sold 4,966,889 shares of common stock at $6.04 per share in a private placement for gross proceeds of $30.0M; registration rights agreement was entered for resale of shares.

    Capital raise provides additional liquidity; increased share count has dilution impact
  • Subsequent events - Maruho Greater Asia milestone

    In October 2026, completion of the Phase 2b clinical trial of EVO756 in CSU triggered a $5.0M development milestone payment to the company under the Maruho Greater Asia Agreement; payment was due within ten business days and will be recognized as revenue in Q4 2026.

    Cash inflow from completed milestone despite EVO756 CSU program discontinuation; Q4 2026 revenue recognition
  • Clinical development - EVO756 discontinued for CSU and AD

    In June 2026, the Phase 2b trial of EVO756 in CSU did not meet its primary endpoint (mean change in UAS7 at 12 weeks); in September 2026, the Phase 2b trial in AD also failed to meet its primary endpoint at any dose; based on these results, the company ceased development of EVO756 for both CSU and AD indications.

    Two major clinical setbacks reduce pipeline value; migraine remains the sole active EVO756 indication
  • Risk factors - new AI risks

    New risk factor added regarding use of AI-powered solutions, including regulatory risks (EU AI Act, state laws), compliance costs, potential data leakage, and competitive disadvantages.

    Expanded regulatory burden and operational risks from AI adoption
  • Risk factors - China dependency and U.S.-China policy risks

    New risk factors added regarding dependence on Hinova (China-based) for EVO570 technology transfer and supply, U.S. regulatory/trade policy risks affecting China-originated drug development, and limited control over Hinova-conducted clinical trials in China.

    Significant geopolitical and operational risks for EVO570 program following Hinova license

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow EVMN in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert